News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk, Inc. (NVO) Shares Seen Volatile Ahead Of FDA Review


3/31/2009 10:44:32 AM

WASHINGTON, March 31 (Reuters) - U.S. regulators will ask an advisory panel to assess heart risks from Novo Nordisk's (NOVOb.CO) proposed diabetes drug liraglutide as well as cases of thyroid tumors seen in rodents, documents released on Tuesday said.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES